Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Innovative Drug Developer Hutchison MediPharma Could See Spin-off Ahead, Says Founder

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The head of Hutchison MediPharma, one of China's most promising developers of innovative drugs, has disclosed that with a series of milestones met over the past months with pipeline medicines, the outfit is mulling whether to become independent via a spin-off

You may also be interested in...



Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner

BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner

Related Content

UsernamePublicRestriction

Register

SC074380

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel